Skip to nav Skip to content
Hany  Elmariah

Hany Elmariah, MD, MS

Program: Blood and Marrow Transplant and Cellular Immunotherapy

Research Program: Immuno-Oncology Program

Contact

  • Overview

    Dr. Elmariah’s research is primarily focused on leading clinical trials designed to optimize haploidentical donor blood and marrow transplantation as a strategy to increase donor availability. He also leads clinical trials developing novel cellular therapies as potential cures for myeloid malignancies.

    Associations

    • Blood and Marrow Transplant and Cellular Immunotherapy
    • Immunology
    • Immuno-Oncology Program

    Education & Training

    Graduate:

    • University of Florida, MS - Biomedical Engineering

    Fellowship:

    • Johns Hopkins Hospital - Hematology and Oncology

    Residency:

    • Duke University Medical Center - Internal Medicine

    Medical School:

    • University of Florida College of Medicine - MD
  • Research Interest

    As a researcher, Dr. Elmariah designs and leads clinical trials focused on haploidentical transplant and post-transplant cyclophosphamide, transplant for myeloid malignancies, and novel cellular therapies for myeloid malignancies. In this capacity, Dr. Elmariah has worked to develop a new treatment approach that is currently under investigation in a trial entitled a "Phase I trial of CD8-depleted HLA mismatched donor lymphocyte infusion (DLI) for Myelodysplastic Syndrome and secondary Acute Myeloid Leukemia. " He is also leading a trial entitled "A prospective phase I/II single center trial of Fedratinib maintenance for Myelofibrosis after Allogeneic Hematopoietic Cell Transplant," which is designed to try to improve cure rates for patients undergoing transplantation for myelofibrosis. Dr. Elmariah also served as the Moffitt site principal investigator for BMT Clinical Trials Network 1703 multicenter phase 3 trial of post-transplant cyclophosphamide versus tacrolimus/methotrexate for GVHD prophylaxis in matched donor transplant, a trial which has changed standard practice for graft-versus-host disease prevention. Dr. Elmariah's research is published has been funded by multiple organizations including a Conquer Cancer Foundation/ASCO Young Investigator Award, an FDA Orphan Grant R01 award, the Winn Diversity in Clinical Trials Career Development Award, and internal Moffitt grants. 

  • Publications

    • Ho TT, Perkins JB, Gonzalez R, Hicks JK, Martinez RA, Duranceau K, North B, Kim J, Teer JK, Yao J, Yoder SJ, Nishihori T, Bejanyan N, Pidala J, Elmariah H. Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients. Pharmacogenomics. 2024 Jan.25(1):29-40. Pubmedid: 38189154.
    • Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, Pourhassan H, Nishihori T, Faramand R, Mishra A, Khimani F, Fernandez H, Lazaryan A, Nieder M, Perez L, Liu H, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Locke F, Bejanyan N, Al Malki MM. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2024 Feb.30(2):229.e1-229.e11. Pubmedid: 37952648.
    • Ionescu F, David JC, Ravichandran A, Sallman DA, Sweet K, Komrokji RS, Chan O, Kuykendall A, Padron E, Faramand R, Bejanyan N, Khimani F, Elmariah H, Pidala J, Mishra A, Perez L, Nishihori T, Lancet JE. Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk. 2024 Feb. Pubmedid: 38429222.
    • Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall S, Gondek L, Bashey A, Keyzner A, Tamari R, Grunwald M, Abedin S, Nadiminti K, Iqbal M, Gerds A, Viswabandya A, McCurdy S, Malki MA, Varadhan R, Ali H, Gupta V, Jones RJ, Otoukesh S. Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration. Res Sq. 2023 Mar. Pubmedid: 36993719. Pmcid: PMC10055643.
    • Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023 Jun.388(25):2338-2348. Pubmedid: 37342922.
    • Ammad Ud Din M, Chowdhury M, Shahzad M, Zahid S, Liaqat H, Osama M, Elmariah H. Trends and in-hospital cardiac complications in patients with atrial fibrillation undergoing allogeneic stem cell transplant: A National Inpatient Sample analysis (2002-2019). Eur J Haematol. 2023 Jun.110(6):754-761. Pubmedid: 36949272.
    • Saad A, Loren A, Bolaños-Meade J, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Elmariah H, Farag S, Gundabolu K, Gutman J, Ho V, Hoeg R, Horwitz M, Hsu J, Kassim A, Kharfan Dabaja M, Magenau J, Martin T, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Ninos C, Oliai C, Patel S, Randolph B, Schroeder M, Tzachanis D, Varshavsky-Yanovsky AN, Vusirikala M, Algieri F, Pluchino LA. NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022. J Natl Compr Canc Ne. 2023 Feb.21(2):108-115. Pubmedid: 36791762.
    • Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall SA, Gondek LP, Bashey A, Keyzner A, Tamari R, Grunwald MR, Abedin S, Nadiminti KV, Iqbal M, Gerds AT, Viswabandya A, McCurdy SR, Al Malki MM, Varadhan R, Ali H, Gupta V, Jones RJ, Otoukesh S. Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration. Haematologica. 2023 Dec.108(12):3321-3332. Pubmedid: 37408464. Pmcid: PMC10690921.
    • Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: 37307173. Pmcid: PMC10424134.
    • Jain T, Tsai HL, DeZern AE, Gondek LP, Elmariah H, Bolaños-Meade J, Luznik L, Fuchs E, Ambinder R, Gladstone DE, Imus P, Webster J, Prince G, Ghiaur G, Smith BD, Ali SA, Ambinder A, Dalton WB, Gocke CB, Huff CA, Gojo I, Swinnen L, Wagner-Johnston N, Borrello I, Varadhan R, Levis M, Jones RJ. Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. Transplant Cell Ther. 2022 May.28(5):259.e1-259.e11. Pubmedid: 35158092. Pmcid: PMC9081210.
    • Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, Iqbal M, Grunwald MR, Dholaria B, Elmariah H, Ozga M, Singh A, Abedin S, DeZern AE, Jones RJ, Gupta V, Gerds AT, Jain T. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia. 2022 Mar.36(3):856-864. Pubmedid: 34663912.
    • Lazaryan A, Lee SJ, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Gonzalez R, Jain MD, Davila ML, Perez LE, Mishra A, Perez Perez A, Balke K, Ayala E, Ochoa L, Castaneda Puglianini O, Faramand RG, Alsina M, Elmariah H, Nieder M, Fernandez H, Anasetti C, Pidala J. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022 Jan.6(1):259-269. Pubmedid: 34649279. Pmcid: PMC8753213.
    • Jain AG, Elmariah H. BMT for Myelodysplastic Syndrome: When and Where and How. Front Oncol. 2022 Jan.11:771614. Pubmedid: 35070975. Pmcid: PMC8770277.
    • Otoukesh S, Elmariah H, Yang D, Clark MC, Siraj M, Ali H, Mogili K, Arslan S, Nishihori T, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Malki MMA, Bejanyan N. Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2022 Feb.28(2):111.e1-111.e8. Pubmedid: 34844022.
    • O'Donnell PV, Brunstein CG, Fuchs EJ, Zhang MJ, Allbee-Johnson M, Antin JH, Leifer ES, Elmariah H, Grunwald MR, Hashmi H, Horowitz MM, Magenau JM, Majhail N, Milano F, Morris LE, Rezvani AR, McGuirk JP, Jones RJ, Eapen M. Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. Transplant Cell Ther. 2022 Feb.28(2):109.e1-109.e8. Pubmedid: 34775146. Pmcid: PMC8882346.
    • Elmariah H. Commentary: Target CD34 Cell Dose for Allogeneic Hematopoietic Cell Transplantation: Can We Finally Agree?. Transplant Cell Ther. 2022 Feb.28(2):59-60. Pubmedid: 35115133.
    • Wood AC, Perez AP, Arciola B, Patel K, Johnson G, DiMaggio E, Bachmeier CA, Reid K, Carallo S, Vargas MH, Faramand R, Chavez JC, Shah B, Gaballa S, Khimani F, Elmariah H, Nishihori T, Lazaryan A, Freeman C, Davila ML, Locke FL, Mhaskar R, Bassil C, Jain MD. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplant Cell Ther. 2022 Dec.28(12):829.e1-829.e8. Pubmedid: 36174934. Pmcid: PMC9791940.
    • Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
    • Mirza AS, Tandon A, Jenneman D, Cao S, Brimer T, Kumar A, Kidd M, Khimani F, Faramand R, Mishra A, Liu H, Nishihori T, Perez L, Lazaryan A, Bejanyan N, Nieder M, Pidala J, Elmariah H. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Apr.28(4):185.e1-185.e7. Pubmedid: 35017119.
    • Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, Faramand R, Hansen D, Alsina M, Ochoa L, Davila M, Anasetti C, Pidala J, Bejanyan N. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. 2021 Nov.27(11):940-948. Pubmedid: 34329754.
    • Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand RG, Davila ML, Nieder ML, Sagatys EM, Holtan SG, Lawrence NJ, Lawrence HR, Blazar BR, Anasetti C, Sebti SM, Betts BC. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clin Cancer Res. 2021 May.27(10):2712-2722. Pubmedid: 33753457. Pmcid: PMC8127396.
    • Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021 Mar.5(5):1154-1163. Pubmedid: 33635333. Pmcid: PMC7948297.
    • Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, Bejanyan N. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021 Mar.27(3):256.e1-256.e7. Pubmedid: 33781526. Pmcid: PMC8711732.
    • Kirtane K, Elmariah H, Chung CH, Abate-Daga D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J Immunother Cancer. 2021 Jul.9(7). Pubmedid: 34301811. Pmcid: PMC8311333.
    • Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, Nieder M, Perez L, Mishra A, Elmariah H, Davila M, Ochoa L, Alsina M, Lazaryan A, Bejanyan N, Hansen D, Jain M, Locke F, Liu H, Pidala J, Shah B, Mhaskar R. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Jul.27(7):620.e1-620.e9. Pubmedid: 33798768.
    • Elmariah H, Naqvi SMH, Kim J, Nishihori T, Mishra A, Perez L, Faramand R, Lazaryan A, Liu HD, Khimani F, Nieder M, Anasetti C, Pidala J, Bejanyan N. Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2021 Jul.56(7):1683-1690. Pubmedid: 33658647.
    • Elmariah H, Brunstein CG, Bejanyan N. Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation. Life (Basel). 2021 Jan.11(2). Pubmedid: 33572932. Pmcid: PMC7911120.
    • Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St Martin A, Bashey A, Battiwalla M, Bredeson CN, Copelan E, Cutler CS, George BR, Gupta V, Kanakry C, Mehta RS, Milano F, Mussetti A, Nakamura R, Nishihori T, Saber W, Solh M, Weisdorf DJ, Eapen M. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Adv. 2021 Feb.5(4):975-983. Pubmedid: 33576783. Pmcid: PMC7903230.
    • DeZern AE, Elmariah H, Zahurak M, Rosner GL, Gladstone DE, Ali SA, Huff CA, Swinnen LJ, Imus P, Borrello I, Wagner-Johnston ND, Ambinder RF, Brodsky RA, Cooke K, Luznik L, Fuchs EJ, Bolaños-Meade J, Jones RJ. Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. Biol Blood Marrow Tr. 2020 Nov.26(11):2075-2081. Pubmedid: 32818556.
    • Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, Zimmerman JW, Hajjir K, Venkatraman D, Armstrong DK, Laheru DA, Mehra R, Ho WJ, Reuss JE, Heng J, Vellanki P, Donehower RC, Holdhoff M, Naidoo J. Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. J Oncol Pract. 2019 Sep.15(9):e825-e834. Pubmedid: 31386608. Pmcid: PMC6743220.
    • Elmariah H, DeZern AE. Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment. Curr Hematol Malig Rep. 2019 Jun.14(3):154-163. Pubmedid: 31093889.
    • Elmariah H, Fuchs EJ. Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results. Semin Hematol. 2019 Jul.56(3):183-189. Pubmedid: 31202428. Pmcid: PMC9229262.
    • Elmariah H, Fuchs EJ. Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results. Semin Hematol. 2018 Sep.
    • Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, Bolaños-Meade J, Fuchs EJ, Wagner-Johnston N, Swinnen LJ, Huff CA, Matsui WH, Gladstone DE, McCurdy SR, Borrello I, Gocke CB, Shanbhag S, Cooke KR, Ali SA, Brodsky RA, DeZern AE, Luznik L, Jones RJ, Ambinder RF. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. Biol Blood Marrow Tr. 2018 May.24(5):1099-1102. Pubmedid: 29452245. Pmcid: PMC6439277.
    • Elmariah H, Shanbhag S. Pan-pseudothrombocytopenia: An unusual case of platelet clumping. Am J Hematol. 2018 Jan. Pubmedid: 29341241.
    • Elmariah H, Thomas S, Boggan JC, Zaas A, Bae J. The Burden of Burnout. Am J Med Qual. 2017 Mar.32(2):156-162. Pubmedid: 26917807.
    • Elmariah H, Pratz KW. Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia. J Natl Compr Canc Ne. 2017 Jul.15(7):959-966. Pubmedid: 28687582.
    • Elmariah H, Garrett ME, De Castro LM, Jonassaint JC, Ataga KI, Eckman JR, Ashley-Koch AE, Telen MJ. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014 May.89(5):530-535. Pubmedid: 24478166. Pmcid: PMC3988218.
    • Rajasekhar A, Elmariah H, Lottenberg L, Beyth R, Lottenberg R, Ang D. Inferior vena cava filters in trauma patients: a national practice patterns survey of U.S. Trauma centers. Am Surg. 2014 Dec.80(12):1237-1244. Pubmedid: 25513923.
    • Welch DE, Elmariah H, Peden MC, Adams SG, Ratnakaram R, Kaushal S. Short-term response of macular oedema to intravitreal bevacizumab. Br J Ophthalmol. 2009 Aug.93(8):1033-1036. Pubmedid: 19403519.
  • Grants

    • Title: γδ T Cell Infusion to Reduce Relapse after HLA Haploidentical Donor Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide
      Sponsor: Bristol Myers Squibb Foundation
      PI: Elmariah, H.
    • Title: Phase I/II Study of CD8-Reduced T Cells for Treatment of Myelodysplastic Syndrome or Acute Myeloid Leukemia IND17305-(12/30/2016)
      Sponsor: US Food & Drug Administration (FDA)
      PI: Elmariah, H.

Find a Researcher Search